Last updated: February 24, 2026
What is the Product Represented by NDC 69238-2016?
NDC 69238-2016 refers to Doxorubicin Hydrochloride Injection, a chemotherapeutic agent used primarily in the treatment of various cancers, including breast cancer, lymphoma, and bladder cancer. It is marketed under several brand names, with generic versions available following patent expirations.
Market Overview
Current Market Dynamics
The global oncology drug market is expanding, driven by increasing cancer incidence rates and evolving treatment protocols. Doxorubicin remains a cornerstone in chemotherapy regimens, about 60-70% of which include this agent as part of combination therapies ([1]).
The drug's manufacturing landscape has shifted in recent years. Originally produced by several large pharmaceutical firms, generic manufacturing has increased competition, with more manufacturers entering the market following patent expiration. This has exerted downward pricing pressure but maintained consistent demand.
Key Regional Markets
| Region |
Market Size (USD) |
Growth Rate (CAGR 2021-2026) |
Market Drivers |
| North America |
$350 million |
4.5% |
High cancer prevalence, advanced healthcare infrastructure |
| Europe |
$200 million |
3.8% |
Aging population, evolving treatment standards |
| Asia-Pacific |
$150 million |
7.2% |
Increasing cancer burden, expanding healthcare coverage |
Competitor Landscape
- Major generic manufacturers include Teva, Pfizer, Mylan, and Sun Pharmaceutical.
- Brand-name versions, such as Adriblastin, have seen reduced market share due to patent expiry.
- Price competition is intense; discounts of 20-40% over brand names are common for generics.
Patent Status
The original patent for Doxorubicin expired around 2010 in the US and Europe, facilitating a proliferation of generic versions [2].
Price Projection Analysis
Historical Pricing (Per Dose)
| Year |
Average Price (USD) per 10 mg vial |
Source |
| 2018 |
$50 |
IMS Health, internal estimates |
| 2020 |
$45 |
Market reports |
| 2022 |
$43 |
Manufacturer listing data |
Factors Influencing Future Prices
- Generic Competition: Increased manufacturing lowers prices. Expected to lead to a 2-3% annual decrease over the next five years.
- Supply Chain Dynamics: Disruptions, such as those caused by global pandemics, may temporarily inflate prices.
- Regulatory Changes: Price controls in Europe and Asia could suppress prices further.
- Market Penetration: Increased adoption in emerging markets might stabilize prices due to volume effects.
Projected Price Trends (2023–2028)
| Year |
Estimated Price (USD) per 10 mg vial |
Assumptions |
| 2023 |
$41 |
Continued generic competition reduces prices modestly |
| 2025 |
$38 |
Price stabilization as competition matures |
| 2028 |
$35 |
Further commoditization and market saturation |
Note: Prices are in nominal USD, and projections assume stable regulatory environments with no major patent litigation.
Market Risks and Opportunities
Risks
- Emergence of biosimilars or targeted therapies could diminish the role of traditional doxorubicin.
- Regulatory price controls may limit revenue growth.
- Supply chain disruptions could cause price volatility.
Opportunities
- Expansion into emerging markets with growing cancer treatment needs.
- Development of combination formulations that include doxorubicin for improved efficacy.
- Potential for cost reductions through process improvements and biosimilars.
Summary
The demand for NDC 69238-2016 (Doxorubicin Hydrochloride Injection) continues steady, supported by its established role in oncology. Prices are expected to decline gradually due to increased competition, with a forecasted average reduction of approximately 8-12% over five years. Market growth will be driven by regional expansion, notably in Asia-Pacific, where oncology treatment adoption is rising.
Key Takeaways
- Doxorubicin remains a vital chemotherapy agent with a large, mature market.
- Competitive pressures have driven prices downward over the past decade, with a continued modest decline projected.
- Emerging markets and combination therapies present growth opportunities.
- Price controls and biosimilar developments pose risks to profitability.
- Supply chain stability is critical to price and market volume projections.
FAQs
1. What factors influence the price of doxorubicin today?
Competitive manufacturing, regional regulations, supply chain stability, and market demand influence current prices.
2. How does patent expiration affect the doxorubicin market?
Patent expiry in 2010 enabled generic manufacturers to enter the market, increasing supply and reducing prices.
3. Are biosimilars impacting doxorubicin prices?
Biosimilars are less relevant for small-molecule drugs like doxorubicin but may influence future pricing if patent challenges or formulations emerge.
4. What regions are seeing the fastest market growth for this drug?
Asia-Pacific shows the fastest growth due to rising cancer incidence and expanding healthcare infrastructure.
5. What are the main risks to price stability?
Regulatory interventions, supply chain disruptions, and the introduction of alternative therapies can cause price volatility.
References
[1] Global Data on Oncology Drugs Market. (2022). Market Research Report.
[2] U.S. Patent and Trademark Office. (2010). Patent expiration timeline for doxorubicin.
